Next Science to Exhibit Surgical Product Portfolio at AAOS 2021
25 August 2021 - 2:11AM
Business Wire
Next Science Limited (ASX:NXS), an innovative medical technology
company, announced that it will exhibit at the American Academy of
Orthopaedic Surgeons (AAOS) annual meeting and conference in San
Diego, California, from Aug. 31 – Sept. 3. Next Science, whose
mission is to heal patients and save lives by addressing the impact
of biofilms on human health, will exhibit at Booth No.
5035.
Next Science will showcase its portfolio of ground-breaking
products, including:
- XPERIENCE™ No Rinse Antimicrobial Solution, a non-toxic
surgical solution that is designed to help prevent surgical site
infections (SSIs) by rinsing away debris and microorganisms;
and
- SURGX®, a topical gel that is applied to a closed surgical
incision to help prevent superficial SSIs.
XPERIENCE and SURGX are both powered by XBIO™ Technology, which
disrupts the biofilm’s extracellular polymeric substance, making
the bacteria within the biofilm more vulnerable to attack.
Biofilms, which are powerful communities of bacteria that function
as a single entity with behaviors and defenses, are a leading
contributor to SSIs.1 2 In the U.S., SSIs contribute an additional
$3.5 billion annually to the cost of healthcare.3 Biofilms account
for more than 80% of microbial infections in the human body,4
according to the U.S. National Institutes of Health.
Next Science also will host a presentation that addresses the
impact of biofilms on SSIs, discusses risk mitigation strategies
and shares clinical results from high-risk patients. The session,
Biofilm and Surgical Site Infections, takes place on
Sept. 1 from 12:40 – 1:25 p.m. in Meeting Room 1 and will be
led by four prominent orthopaedic surgeons:
- Dr. Robert Harris, Hughston Clinic
- Dr. Jon E. Minter, Northside Hospital
- Dr. Randall Otto, SSM Health
- Dr. Ravi K. Bashyal, NorthShore University Hospital
To learn more about Next Science and its innovative products,
stop by Booth No. 5035 or email us at
info@nextscience.com.
About Next Science
Next Science is a medical technology company headquartered in
Sydney, Australia, with a research and development center in
Florida, USA. Established in 2012, the Company’s primary focus is
on the development and continued commercialization of products
powered by its proprietary XBIO Technology to reduce the impact of
biofilm-based infections in human health. XBIO is a unique,
non-toxic technology with proven efficacy in eradicating both
biofilm-based and free-floating bacteria. For further information
visit: www.nextscience.com.
Forward looking statements
This announcement may contain forward looking statements which
may be identified by words such as “believes”, “considers”,
“could”, “estimates”, “expects”, “intends”, “may”, and other
similar words that involve risks and uncertainties. Such statements
are not guarantees of future performance and involve known and
unknown risks, uncertainties, assumptions and other important
factors, many of which are beyond the control of Next Science or
its Directors and management, and could cause Next Science’s actual
results and circumstances to differ materially from the results and
circumstances expressed or anticipated in these statements. The
Directors cannot and do not give any assurance that the results,
performance or achievements expressed or implied by the
forward-looking statements contained in this announcement will
actually occur and investors are cautioned not to place undue
reliance on these forward-looking statements.
1 International Wound Infection Institute (IWII) Wound infection
in clinical practice. Wounds International. 2 Hall-Stoodley L,
Stoodley P. Evolving concepts in biofilm infections. Cell
Microbiol. 2009;11(7):1034-43. 3 Zimlichman, E., et al., “Health
Care-Associated Infections. A Meta-analysis of Costs and Financial
Impact on the US Health Care System”. JAMA Intern Med, 173(22):
(2013): 2039-46. 4 Joo HS, Otto M. Molecular basis of in-vivo
biofilm formation by bacterial pathogens. Chemistry & Biology.
2012;19(12):1503-1513.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210824005699/en/
Anthony Priwer Dalton Agency Phone: +1 615.515.4891 Email:
apriwer@daltonagency.com
Next Science (ASX:NXS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Next Science (ASX:NXS)
Historical Stock Chart
From Nov 2023 to Nov 2024